Evolent Health [EVH] vs 10x Genomics [TXG] Detailed Stock Comparison
Evolent Health
NYSE
Loading...
10x Genomics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Evolent Health wins in 13 metrics, 10x Genomics wins in 5 metrics, with 0 ties. Evolent Health appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Evolent Health | 10x Genomics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -11.11 | -8.79 | Evolent Health |
| Price-to-Book Ratio | 1.16 | 2.17 | Evolent Health |
| Debt-to-Equity Ratio | 75.85 | 11.22 | 10x Genomics |
| PEG Ratio | -0.02 | 0.05 | Evolent Health |
| EV/EBITDA | 27.33 | -11.86 | 10x Genomics |
| Profit Margin (TTM) | -5.94% | -13.13% | Evolent Health |
| Operating Margin (TTM) | 0.64% | -2.63% | Evolent Health |
| EBITDA Margin (TTM) | 0.64% | N/A | N/A |
| Return on Equity | -11.04% | -11.30% | Evolent Health |
| Return on Assets (TTM) | -0.21% | -9.45% | Evolent Health |
| Free Cash Flow (TTM) | $-6.13M | $-6.73M | Evolent Health |
| 1-Year Return | -73.40% | -44.23% | 10x Genomics |
| Price-to-Sales Ratio (TTM) | 0.48 | 2.60 | Evolent Health |
| Enterprise Value | $1.97B | $1.32B | Evolent Health |
| EV/Revenue Ratio | 0.90 | 2.04 | Evolent Health |
| Gross Profit Margin (TTM) | 22.59% | 72.34% | 10x Genomics |
| Revenue per Share (TTM) | $19 | $5 | Evolent Health |
| Earnings per Share (Diluted) | $-1.60 | $-0.70 | 10x Genomics |
| Beta (Stock Volatility) | 0.82 | 2.03 | Evolent Health |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Evolent Health vs 10x Genomics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Evolent Health | -2.12% | -0.57% | -10.14% | 9.63% | -15.92% | -23.67% |
| 10x Genomics | -1.95% | -1.06% | 13.52% | 57.45% | 20.18% | -7.68% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Evolent Health | -73.40% | -76.04% | -35.75% | -48.92% | -53.50% | -53.50% |
| 10x Genomics | -44.23% | -62.45% | -88.12% | -74.94% | -74.94% | -74.94% |
Performance & Financial Health Analysis: Evolent Health vs 10x Genomics
| Metric | EVH | TXG |
|---|---|---|
| Market Information | ||
| Market Cap | $1.04B | $1.68B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 4,274,290 | 3,765,720 |
| 90 Day Avg. Volume | 2,970,243 | 3,297,403 |
| Last Close | $8.77 | $13.10 |
| 52 Week Range | $7.06 - $33.63 | $6.78 - $24.76 |
| % from 52W High | -73.92% | -47.09% |
| All-Time High | $39.78 (Sep 12, 2022) | $208.99 (Jun 28, 2021) |
| % from All-Time High | -77.95% | -93.73% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.31% | 0.13% |
| Quarterly Earnings Growth | N/A | 0.13% |
| Financial Health | ||
| Profit Margin (TTM) | -0.06% | -0.13% |
| Operating Margin (TTM) | 0.01% | -0.03% |
| Return on Equity (TTM) | -0.11% | -0.11% |
| Debt to Equity (MRQ) | 75.85 | 11.22 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $7.73 | $6.21 |
| Cash per Share (MRQ) | $1.30 | $3.59 |
| Operating Cash Flow (TTM) | $-33,330,000 | $66.95M |
| Levered Free Cash Flow (TTM) | $-77,390,624 | $58.22M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Evolent Health vs 10x Genomics
| Metric | EVH | TXG |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -11.11 | -8.79 |
| Forward P/E | 6.29 | -11.03 |
| PEG Ratio | -0.02 | 0.05 |
| Price to Sales (TTM) | 0.48 | 2.60 |
| Price to Book (MRQ) | 1.16 | 2.17 |
| Market Capitalization | ||
| Market Capitalization | $1.04B | $1.68B |
| Enterprise Value | $1.97B | $1.32B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.90 | 2.04 |
| Enterprise to EBITDA | 27.33 | -11.86 |
| Risk & Other Metrics | ||
| Beta | 0.82 | 2.03 |
| Book Value per Share (MRQ) | $7.73 | $6.21 |
Financial Statements Comparison: Evolent Health vs 10x Genomics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | EVH | TXG |
|---|---|---|
| Revenue/Sales | $483.65M | $154.88M |
| Cost of Goods Sold | $381.18M | $49.44M |
| Gross Profit | $102.47M | $105.45M |
| Research & Development | N/A | $64.25M |
| Operating Income (EBIT) | $4,000 | $-48.53M |
| EBITDA | $25.27M | $-32.89M |
| Pre-Tax Income | $-63.15M | $-33.51M |
| Income Tax | $1.47M | $852,000 |
| Net Income (Profit) | $-64.62M | $-34.36M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | EVH | TXG |
|---|---|---|
| Cash & Equivalents | $246.55M | $377.06M |
| Total Current Assets | $727.93M | $579.73M |
| Total Current Liabilities | $739.10M | $107.90M |
| Long-Term Debt | $663.12M | $70.63M |
| Total Shareholders Equity | $935.52M | $706.90M |
| Retained Earnings | $-845.44M | $-1.50B |
| Property, Plant & Equipment | $5.73M | $55.58M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | EVH | TXG |
|---|---|---|
| Operating Cash Flow | $-23.39M | $35.44M |
| Capital Expenditures | N/A | $-1.89M |
| Free Cash Flow | $-4.03M | $32.46M |
| Debt Repayment | $-62.50M | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | EVH | TXG |
|---|---|---|
| Shares Short | 18.83M | 14.46M |
| Short Ratio | 7.11 | 4.59 |
| Short % of Float | 0.16% | 0.19% |
| Average Daily Volume (10 Day) | 4,274,290 | 3,765,720 |
| Average Daily Volume (90 Day) | 2,970,243 | 3,297,403 |
| Shares Outstanding | 115.04M | 122.29M |
| Float Shares | 91.32M | 112.38M |
| % Held by Insiders | 0.02% | 0.02% |
| % Held by Institutions | 1.09% | 1.05% |
Dividend Analysis & Yield Comparison: Evolent Health vs 10x Genomics
| Metric | EVH | TXG |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |